Figure 3.

Potentiation of CD47 antibody and CPMV for treatment of 4T1 and ID8-Defb29/Vegf-A tumors. A-B. BALB/c mice were implanted intradermally with 4T1 mammary carcinoma cells (1.25× 10⁵) on the right flank. Mice were treated with PBS, 70 μg of CPMV, 100 μg CD47 Ab, or combination on day 10 and day 17 post-tumor challenge (indicated by black arrow). A. Tumor growth curves shown as relative tumor volume. Growth curves were stopped when the first animal of the corresponding group was sacrificed (tumor volume ≥ 1000 mm³). Statistical significance (on day 32) was calculated by two-way ANOVA with Tukey test. ***p<0.0005, ****p<0.0001. B. Survival rates of treated and control mice. Statistical significance of survival was calculated by Log-rank (Mantel-Cox) test. **p<0.01. C-D. ID8-Defb29/Vegf-A tumor-challenged C57BL/6 mice were treated with 30 μg of CPMV, 100 μg CD47 Ab, or combination weekly beginning on day 7 post-tumor challenge (indicated by black arrow). C. Tumor growth was followed by measuring the luciferase expression in peritoneal cavity. Statistical significance (on day 56) was calculated by two-way ANOVA with Tukey test. ***p<0.0005, ****p<0.0001. Growth curves were stopped when the first animal of the corresponding group was sacrificed (weight ≥ 33 grams). D. Survival rates of treated and control mice. Data are means ± SEM (n=4–5). Statistical significance of survival was calculated by Log-rank (Mantel-Cox) test. **p<0.01.